Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery

Richard T. Maziarz, Amber Diaz, David B. Miklos, Nirav N. Shah

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

Host immune depletion has been recognized as a necessary step for successful adoptive immune cell transfer in both the autologous and allogeneic settings. The chemotherapy agent fludarabine as an immune suppressive agent has a central role in multiple conditioning regimens for both transplantation and immune effector cell therapies. With the recent and sudden recognition of an imminent worldwide fludarabine shortage, novel approaches to overcome supply chain disruption are needed, including exploration of alternative therapies. The fludarabine shortage has highlighted the need to prioritize the development of institutional algorithms for maintaining ongoing clinical trials and standard of care procedures in the setting of critical drug shortages.

Original languageEnglish (US)
Pages (from-to)723-726
Number of pages4
JournalTransplantation and Cellular Therapy
Volume28
Issue number11
DOIs
StatePublished - Nov 2022

Keywords

  • CAR-T
  • Drug shortage
  • Fludarabine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Molecular Medicine
  • Hematology
  • Cell Biology
  • Transplantation

Fingerprint

Dive into the research topics of 'Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery'. Together they form a unique fingerprint.

Cite this